Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Biotechnology
Healthcare
Get real-time and historical exchange rates for any currency!
Get real-time and historical stock ticker prices for US stocks!
Translate cryptic bank transactions into merchants with logos, address and more!
Brought to you by Synth, a modern fintech API for modern businesses